Previous Close | 0.9730 |
Open | 0.9700 |
Bid | N/A x N/A |
Ask | N/A x N/A |
Day's Range | 0.9700 - 0.9700 |
52 Week Range | 0.4200 - 1.2500 |
Volume | |
Avg. Volume | 6,406 |
Market Cap | 11.046M |
Beta (5Y Monthly) | 0.84 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.9640 |
Earnings Date | Mar 27, 2023 - Mar 31, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
MISSISSAUGA, Ontario & MONTREAL, Quebec, December 23, 2022--Nuvo Pharmaceuticals Inc. d/b/a Miravo Healthcare (TSX:MRV; OTCQX:MRVFF) ("Miravo" or the "Company") and Searchlight Pharma Inc., a private Canadian-based specialty healthcare company ("Searchlight" or the "Purchaser"), are pleased to announce that they have entered into a definitive agreement (the "Arrangement Agreement") pursuant to which the Purchaser has agreed to acquire all of the issued and outstanding common shares of the Compan
MISSISSAUGA, Ontario, November 14, 2022--Nuvo Pharmaceuticals Inc. (TSX:MRV; OTCQX:MRVFF) d/b/a Miravo Healthcare (Miravo or the Company), a Canadian-focused healthcare company with global reach and a diversified portfolio of commercial products, today announced its financial and operational results for the three and nine months ended September 30, 2022. For further details on the results, please refer to Miravo’s Management, Discussion and Analysis (MD&A) and Condensed Consolidated Interim Fina
MISSISSAUGA, Ontario,, October 31, 2022--Nuvo Pharmaceuticals Inc. (TSX:MRV; OTCQX:MRVFF) d/b/a Miravo Healthcare (Miravo or the Company), a Canadian focused, healthcare company with global reach and a diversified portfolio of commercial products, today announced it expects to release its third quarter 2022 financial results before markets open on Monday, November 14, 2022.